N'-(4-methylpentyl)propane-1,3-diamine | 22078-11-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N'-(4-methylpentyl)propane-1,3-diamine
• CAS: 22078-11-1
• 化学式: C₉H₂₂N₂
• 分子量: 158.287
• InChiKey: MDKWXNZTOLRIIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 2-(hydroxyimino)acetate 、 N'-(4-methylpentyl)propane-1,3-diamine 生成 2-(hydroxyimino)-N-(3-((4-methylpentyl)amino)propyl)acetamide
  参考文献：
  名称：

  Reactivators of cholinesterase

  摘要：

  DOI：

  10.1007/bf00759399

文献信息

• [EN] TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE MÉTHYLTRANSFÉRASES
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2019036384A1

  公开（公告）日：2019-02-21

  The present disclosure provides tricyclic compounds of formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了式（I）的三环化合物，它们是组蛋白甲基转移酶G9a和/或GLP抑制剂，因此可用于治疗通过抑制G9a和/或GLP可治疗的疾病，如癌症和血红蛋白病（例如β地中海贫血和镰刀细胞病）。还提供了含有这类化合物的药物组合物以及制备这类化合物的方法。
• [EN] LIPIDATED CATIONIC PEPTIDE-PEG COMPOSITIONS FOR NUCLEIC ACID DELIVERY<br/>[FR] COMPOSITIONS DE PEPTIDE-PEG CATIONIQUE LIPIDÉ DESTINÉES À L'ADMINISTRATION D'ACIDES NUCLÉIQUES
  申请人：NUTCRACKER THERAPEUTICS INC

  公开号：WO2021030218A1

  公开（公告）日：2021-02-18

  The present disclosure relates to complexes and compositions of cationic compounds combined with low mass percentages of PEGylated compounds, such as PEGylated lipids, for the delivery of nucleic acids and other polyanionic cargoes to cells, methods for preparing complexes and compositions comprising one or more cationic compounds and a low mass percentage of PEGylated compounds with polyanionic compounds, and methods for delivering the polyanionic compounds to cells.

  本公开涉及与PEG化化合物（如PEG化脂质）结合的阳离子化合物复合物和组合物，用于将核酸和其他多阴离子载体传递给细胞，制备包含一种或多种阳离子化合物和低质量百分比PEG化化合物与多阴离子化合物的复合物和组合物的方法，以及将多阴离子化合物传递给细胞的方法。
• [EN] ANTIMICROBIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIMICROBIENS
  申请人：CURZA GLOBAL LLC

  公开号：WO2019013789A1

  公开（公告）日：2019-01-17

  Disclosed are compounds of formula I: or pharmaceutically acceptable salts thereof. Compounds of formula I are anti-microbials that inhibit, for instance, Mycobacterium tuberculosis (Mtb) H37Ra. Compounds of formula I also have anti-tubercular activity, exhibit limited cytotoxicity, and inhibit protein synthesis. Processes for making compounds of formula I are also disclosed, as well as methods of using compounds of formula I for the treatment of bacterial infections, particularly tuberculosis.

  公开的是I式化合物：或其药用可接受的盐。I式化合物是抗微生物的，例如抑制结核分枝杆菌（Mtb）H37Ra的。I式化合物还具有抗结核活性，表现出有限的细胞毒性，并且抑制蛋白质合成。公开了制备I式化合物的方法，以及使用I式化合物治疗细菌感染，特别是结核病的方法。
• [EN] ANTIMICROBIAL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ANTIMICROBIENS ET LEURS UTILISATIONS
  申请人：CURZA GLOBAL LLC

  公开号：WO2019013790A1

  公开（公告）日：2019-01-17

  Disclosed are compounds of formula I: or pharmaceutically acceptable salts thereof. Compounds of formula I are anti-microbials that inhibit, for instance, Mycobacterium tuberculosis (Mtb) H37Ra. Compounds of formula I also have anti-tubercular activity, exhibit limited cytotoxicity, and inhibit protein synthesis. Processes for making compounds of formula I are also disclosed, as well as methods of using compounds of formula I for the treatment of bacterial infections, particularly tuberculosis.

  本发明涉及公式I的化合物或其药学上可接受的盐。公式I的化合物是抗微生物的，例如抑制结核分枝杆菌（Mtb）H37Ra。公式I的化合物也具有抗结核活性，表现出有限的细胞毒性，并抑制蛋白质合成。本发明还揭示了制备公式I的化合物的方法，以及使用公式I的化合物治疗细菌感染，特别是结核病的方法。
• MODIFIED BLOCK COPOLYMER, METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER, AND RESIN COMPOSITION
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：EP3623398A1

  公开（公告）日：2020-03-18

  A modified block copolymer according to the present invention is a modified block copolymer comprising a polymer block comprising a vinyl aromatic compound as a main constituent (A), a polymer block comprising a conjugate diene compound as a main constituent (B), and an atomic group having NHx (x = 0 to 2) (C). In the modified block copolymer, the polymer block comprising a conjugate diene compound as a main constituent (B) is a hydrogenated product, the atomic group having NHx (x = 0 to 2) (C) is contained in a side chain, and a compound forming the atomic group having NHx (x = 0 to 2) (C) satisfies the following condition: Condition: when the compound forming the atomic group having NHx (x = 0 to 2) (C) is reacted with a maleic anhydride-modified group in a maleic anhydride-modified block copolymer, a MFR value at 230°C under a load of 2.16 kg of the modified block copolymer after the reaction is 0.1 times or more a MFR value at 230°C under a load of 2.16 kg of the maleic anhydride-modified block copolymer before the reaction.

  根据本发明，改性嵌段共聚物是一种改性嵌段共聚物，包括以乙烯基芳香族化合物为主要成分的聚合物嵌段（A）、以共轭二烯化合物为主要成分的聚合物嵌段（B）和具有 NHx（x = 0 至 2）的原子团（C）。在改性嵌段聚合物中，由共轭二烯化合物作为主要成分（B）的聚合物嵌段是氢化产物，具有 NHx（x = 0 至 2）（C）的原子团包含在侧链中，形成具有 NHx（x = 0 至 2）（C）的原子团的化合物满足以下条件： 条件：当形成具有 NHx（x = 0 至 2）(C)的原子团的化合物与马来酸酐改性嵌段共聚物中的马来酸酐改性基团反应时，反应后在 230℃、负载 2.16 千克改性嵌段共聚物时的 MFR 值是反应前在 230℃、负载 2.16 千克马来酸酐改性嵌段共聚物时的 MFR 值的 0.1 倍或以上。